Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1994-4-8
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0098-1532
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
22
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
358-9
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8127262-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8127262-Drug Synergism,
pubmed-meshheading:8127262-Humans,
pubmed-meshheading:8127262-Hydroxyurea,
pubmed-meshheading:8127262-Infant,
pubmed-meshheading:8127262-Interferon-alpha,
pubmed-meshheading:8127262-Leukemia, Myelogenous, Chronic, BCR-ABL Positive
|
pubmed:year |
1994
|
pubmed:articleTitle |
Interferon-alpha-2 (IFN) plus hydroxyurea for treatment of juvenile chronic myelogenous leukemia.
|
pubmed:publicationType |
Letter,
Comment
|